Zydus Lifesciences is currently trading at RS. 997.60, up by 2.85 points or 0.29% from its previous closing of RS. 994.75 on the BSE.

The stock opened at RS. 999.25 and has touched an intraday high of RS. 999.95 and a low of RS. 989.65. A total of 9899 shares have been traded on the counter so far.

The BSE group 'A' stock, with a face value of RS. 1, has marked a 52-week high of RS. 1323.90 on August 9, 2024, and a 52-week low of RS. 797.05 on April 7, 2025. Over the past week, the stock's high and low stood at RS. 999.95 and RS. 960.60 respectively. The company’s current market capitalization is RS. 100386.93 crore.

Promoter holding in the company stands at 74.99%, while institutional and non-institutional investors hold 18.26% and 6.74%, respectively.

In a strategic development, Zydus Lifesciences’ step-down subsidiary, Zydus MedTech (France) SAS, has completed the block acquisition of 85.6% equity shares of France-based Amplitude Surgical SA. With this, Zydus MedTech France now controls 85.6% of the share capital and voting rights of the target entity.

On July 30, 2025, Zydus MedTech France will file a simplified mandatory tender offer for the remaining outstanding shares of Amplitude Surgical at a price of Euro 6.25 per share, consistent with the block acquisition rate. With commitments from seven shareholders representing an additional 4.7% of the company’s capital and voting rights, Zydus is poised to exceed the 90% ownership threshold, paving the way for a squeeze-out process.

Zydus Lifesciences, formerly Cadila Healthcare, is an integrated pharmaceutical company headquartered in India. It operates across the entire pharmaceutical value chain including research, development, manufacturing, marketing, and distribution of pharmaceutical products.